BPC-157 + TB-500 10mg Wolverine Blend

Blend: BPC‑157 + TB‑500, 10 mg total (5 mg each). Lyophilized powder—USA-made, ≥99% pure.

For laboratory research only. Not for human or veterinary use.

Batch tested for purity ≥99%. Full COA available upon request—email providers@theratideusa.com.

• Wound & tissue repair: Both peptides enhance angiogenesis, fibroblast migration, collagen synthesis, and reduce inflammation and oxidative stress :contentReference[oaicite:1]{index=1}.
• Mechanisms: BPC‑157 upregulates VEGFR2 and FAK‑paxillin pathways; TB‑500 modulates actin dynamics and VEGF expression :contentReference[oaicite:2]{index=2}.
• Synergy: The combination may accelerate healing more than either alone by addressing blood vessel growth, cell migration, and matrix remodeling :contentReference[oaicite:3]{index=3}.
• Neuroprotective & cardiovascular benefits: Preclinical studies show neuroprotective effects in CNS injuries and heart tissue; both reduce oxidative stress :contentReference[oaicite:4]{index=4}.

Data derived from animal studies and small clinical trials; human efficacy is not yet established.

Why use this blend?
It's designed to leverage complementary mechanisms—angiogenesis (BPC‑157), cell migration (TB‑500), and enhanced healing outcomes.

How to use?
Reconstitute with sterile water and administer per laboratory protocols (e.g., IM, IV).

Is oral use effective?
BPC‑157 shows high oral bioavailability; TB‑500 is typically injected to ensure absorption.

Any side effects?
Generally well tolerated in animal studies. May cause mild injection-site irritation or transient soreness :contentReference[oaicite:5]{index=5}.

For research use only—NOT intended for human or veterinary use or as dietary supplements.

Safety: Handle in accordance with laboratory protocols, use PPE, and store at ≤ –20 °C.

FDA Notice: Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.